| Thiol activation and oxidation |
| Low conjugation efficiency |
Thiol oxidation before coupling or incomplete deprotection/reduction. |
Use freshly reduced thiol, minimize air exposure, and confirm reducing conditions are compatible with the payload. |
Routine
|
| Unexpected disulfide formation |
Free thiol oxidation during storage, shipment, or prolonged handling. |
Order protected thiol formats and reduce immediately before conjugation. |
Routine
|
| Variable reproducibility |
Inconsistent reduction time, pH, buffer composition, or reaction timing. |
Standardize reduction, buffer, pH, reaction time, and purification workflow. |
Review
|
| Spacer and payload accessibility |
| Poor protein labeling |
Spacer is too short or the protein/antibody is sterically crowded. |
Select C12, TEG, PEG6, or PEG12 thiol spacing to improve accessibility. |
Review
|
| Low surface coverage |
Limited accessibility of the thiol or unfavorable surface presentation. |
Increase spacer length, use PEG/TEG linkers, and optimize immobilization conditions. |
Review
|
| Hydrophobic conjugate behavior |
Lipid, cholesterol, dye, or drug-like payload changes solubility and retention. |
Consider PEG spacers and plan purification method development before synthesis. |
Technical
|
| Nanoparticle and surface workflows |
| Gold nanoparticle aggregation |
High oligo density, rapid salt addition, or insufficient colloidal stabilization. |
Optimize loading density and use gradual salt-aging or project-specific stabilization conditions. |
Review
|
| Weak biosensor signal |
Surface density, linker length, or target accessibility is not optimized. |
Evaluate C12/TEG/PEG spacers, oligo density, and orientation on the surface. |
Review
|
| Multifunctional and analytical complexity |
| Competing reactions |
Multiple reactive groups are present without a defined reaction order. |
Use orthogonal multifunctional designs and define the reaction sequence before conjugation. |
Technical
|
| Difficult purification |
Large hydrophobic payload, long PEG, multiple reactive handles, or mixed products. |
Plan HPLC method and analytical QC before synthesis; consider LC-MS/MALDI when feasible. |
Technical
|
| Therapeutic-style complexity |
Payload stability, stoichiometry, linker cleavage, and release testing are not defined early. |
Request scientist review for linker, protection, conjugation, purification, and QC strategy. |
Advanced
|